#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Brendon Stiles @BrendonStilesMD Excited for everyone to be here. Yes it was #WCLC20 , but it was a great way to start 2021! #lcsm |
 | Henning Willers, MD @HenningWillers @HenningWillers #radonc #physicianscientist @MGHCancerCenter here, Trying to participate while fighting off kids (I might not win this one though ;-) ...) #lcsm |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @JAMAOnc: The ADAURA trial showed an unprecedented improvement in DFS with adjuvant osimertinib in resected EGFR+ NSCLC, so is it time to recommend it? The answer is a clear and unequivocal yes! https://t.co/SjhXno98iB #LCSM |
 | Lung Cancer Sux @LungCancerSux Glorianne from CT. Caregiver. Hubby is >10 years stage IV #LCSM |
| Brendon Stiles @BrendonStilesMD #wclc20 was yet another great meeting from @iaslc. Certainly the best multidisciplinary meeting I am a part of. #lcsm |
 | Charu Aggarwal, MD, MPH @CharuAggarwalMD @BrendonStilesMD Hi everyone, joining in from Philly! Med Onc at @PennCancer. Good to see everyone! #LCSM |
| Brendon Stiles @BrendonStilesMD I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
 | Stephen V Liu, MD @StephenVLiu RT @LungCancerFaces: ATTENTION #LCSM! Less than 30 minutes until #LCSM Chat. Please join moderator @BrendonStilesMD as he presents “#WCLC20 from the comfort of your own home.” Read more here: https://t.co/Q3tREX1ovl See you at 5pm PT, 8pm ET! |
| Brendon Stiles @BrendonStilesMD That said….it has been a great year for lung cancer. This was obvious at #wclc20 #lcsm |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD @PennCancer Hi Charu! #lcsm |
 | LungCancer.net @LungCancer_HU Margot here! #LCSM |
 | Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
 | K.B. @kbutler127 RT @lgreco_ny: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Why won't New York vaccinate the vulnerable? #lcsm #bcsm @NYGovCuomo https://t.co/w2KqFmCbm7 via @TimesUnion |
 | Faces of Lung Cancer @LungCancerFaces Deana in Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight. Join us now. https://t.co/WrClVC9owF #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @BrendonStilesMD Tremendous year! #LCSM |
| Brendon Stiles @BrendonStilesMD For tonight’s chat: more info at https://t.co/Lx9qF406C9 #lcsm |
 | caius kim @caiuskim Caius here. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD Amen. Ready for some in-person cameraderie! #LCSM |
 | Watch Your Charts @watchyourcharts @BrendonStilesMD QUESTION: Why there is no urgency to find cure for lung cancer by employing AI technology, expediting trials, pressuring scientists to find cure within 6-8 month deadline? My mom's life was already taken by cancer, it was a horrendous death. #LCSM |
| Brendon Stiles @BrendonStilesMD You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: @BrendonStilesMD Amen. Ready for some in-person cameraderie! #LCSM |
 | #LCSM Chat @lcsmchat @LungCancer_HU Hey Margot! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Janet here from overcast Seattle. Glad to "see" my #LCSM tweeps again! |
| Brendon Stiles @BrendonStilesMD To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm |
| #LCSM Chat @lcsmchat @LungCancerSux Hey Glorianne! #lcsm |
 | Jill Feldman @jillfeldman4 #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss seeing everyone IRL #LCSM |
 | Lisa Cunningham @LisaGemini Me too! And I want the CCP punished! |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD https://t.co/yIbKJBgfWO is also a good one #lcsm |
| #LCSM Chat @lcsmchat @HenningWillers @MGHCancerCenter We’ll hope for the best. #lcsm |
 | Eric Bernicker @EricBernicker Happy to be here. Eric, a thoracic medical oncologist from Houston. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @jillfeldman4 @Jbauml @StephenVLiu Miss seeing you Jill, your talk was incredible! 🤗 #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers Indeed. tchat giving me trouble tonight! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: That said….it has been a great year for lung cancer. This was obvious at #wclc20 #lcsm |
| Janet Freeman-Daily @JFreemanDaily @watchyourcharts @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can read tonight's topic questions here: https://t.co/g6Dul2e8Mw |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: For tonight’s chat: For tonight’s chat: more info at https://t.co/Lx9qF406C9 #lcsm |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that my dad died from lung cancer. #LCSM https://t.co/nHFeKsKOXN |
| #LCSM Chat @lcsmchat @caiuskim Welcome! Thanks for joining us. #lcsm |
 | Deb Smith 🌻 @debsmithbeach Deb from NH here. In Boston tonight, scans early tomorrow. #LCSM |
| Brendon Stiles @BrendonStilesMD @MattSmeltzer Hi Matt! #lcsm |
 | kristen kimball @KimballKristen Kris here from Boston, hello! #LCSM |
 | Dr. Marcos Galasso🇨🇦🇧🇷 @GalassoMarcos RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
| Brendon Stiles @BrendonStilesMD I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnews @genentech & others. These don’t affect opinions expressed tonight. #lcsm |
| #LCSM Chat @lcsmchat @watchyourcharts @BrendonStilesMD We can certainly discuss this after tonight’s chat. I lost my mom to lung cancer, too. xo #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Brendon Stiles @BrendonStilesMD In this week’s chat we hope to review some lung cancer highlights from #WCLC20 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm |
 | Dave Bjork @bjork5 @BrendonStilesMD Hey @BrendonStilesMD sorry I’m late! Dave here joining from Boston 🙌 #LCSM |
 | Lillian Leigh @ProjectBreath Joining the conversation now - hello all #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss seeing everyone IRL #LCSM |
 | Matthew Smeltzer @MattSmeltzer Hi everyone! Matt from Memphis #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD https://t.co/yIbKJBgfWO is also a good one #lcsm |
| #LCSM Chat @lcsmchat @EricBernicker Yay! Welcome. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @SueMcCu30398663 Good to see you Sue! #LCSM |
 | Laura Greco @lgreco_ny Hello! Laura here. Greetings from upstate NY #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @watchyourcharts @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can read tonight's topic questions here: https://t.co/g6Dul2e8Mw |
| Brendon Stiles @BrendonStilesMD @bjork5 Dave....my man. Thanks for joining! #LCSM If you haven't heard his podcasts, you are missing out! |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that my dad died from lung cancer. #LCSM https://t.co/nHFeKsKOXN |
| Lillian Leigh @ProjectBreath RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that my dad died from lung cancer. #LCSM https://t.co/nHFeKsKOXN |
| Dave Bjork @bjork5 @CharuAggarwalMD @BrendonStilesMD Hey Charu! #lcsm |
| Brendon Stiles @BrendonStilesMD @ProjectBreath Hi Lillian! #lcsm |
| #LCSM Chat @lcsmchat @debsmithbeach Best hopes, Deb. #lcsm |
| #LCSM Chat @lcsmchat @KimballKristen Hey lady! #lcsm |
| Dave Bjork @bjork5 RT @jillfeldman4: #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss seeing everyone IRL #LCSM |
| Brendon Stiles @BrendonStilesMD #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT |
 | Peggy Dennis @peggyddennis #lcsm. Peggy joining a bit late from Denver |
| #LCSM Chat @lcsmchat @ProjectBreath Woo HOO! Hello! #lcsm |
| Brendon Stiles @BrendonStilesMD Here are t@APassaroMD top 5 presentations https://t.co/6iLv2xb3Bc #lcsm |
| Dave Bjork @bjork5 @debsmithbeach Good luck 🙏🏽 #lcsm |
| Jill Feldman @jillfeldman4 RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT |
| #LCSM Chat @lcsmchat @MattSmeltzer Welcome! #lcsm |
| Brendon Stiles @BrendonStilesMD We will get started soon. First, a few reminders… #lcsm |
 | ann price @aepriceny @lcsmchat ann price here survivor, just retired this week, so I can enjoy my life--here to listen #lcsm |
| Brendon Stiles @BrendonStilesMD Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| Dave Bjork @bjork5 @KimballKristen Boston is representing tonight! #LCSM |
| Henning Willers, MD @HenningWillers @BrendonStilesMD hmmpf, as usual no #radonc advances (we need to do better) #lcsm |
| Janet Freeman-Daily @JFreemanDaily Why do I get the feeling I'm not seeing all the tweets in #LCSM Chat? I see replies, but can't always see the original messages. **sigh** |
| Brendon Stiles @BrendonStilesMD If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
 | Christine Qiong Wu @wi_qiong @lgreco_ny Hi Laura #LCSM |
| #LCSM Chat @lcsmchat @SueMcCu30398663 @JFreemanDaily Hi Sue! Remember to include #lcsm in your tweets and you’ll be just fine. |
| Brendon Stiles @BrendonStilesMD I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Nate Pennell, oncologist in Cleveland! Hi all. #lcsm |
 | Denise A Croix, PhD @CroixDenise Hello! #LCSM |
| Lillian Leigh @ProjectBreath @BrendonStilesMD Hello! Looking forward to today's #LCSM chat and to seeing you at tomorrow's @IASLC STARS! |
| #LCSM Chat @lcsmchat @lgreco_ny Hey spitfire! #lcsm |
 | mimiprovenzano @MimiProvenzano Hi everybody, sorry I'm late! #LCSM |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| #LCSM Chat @lcsmchat @peggyddennis Hi Peggy #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Here are t@APassaroMD top 5 presentations https://t.co/6iLv2xb3Bc #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers Too many to describe! #lcsm |
| #LCSM Chat @lcsmchat @aepriceny Hi Ann! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We will get started soon. First, a few reminders… #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| kristen kimball @KimballKristen @lcsmchat Hey there, Deana! #LCSM |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @BrendonStilesMD We can't cover everything in one hour! I believe some #radonc advances were presented in the #STS conference on the same weekend as #WCLC20. #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD hmmpf, as usual no #radonc advances (we need to do better) #lcsm |
| Dave Bjork @bjork5 @BrendonStilesMD You rock this Brendon! #LCSM |
 | Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh #lcsm hello everyone Kim here from Canada |
| Brendon Stiles @BrendonStilesMD T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
 | Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @JFreemanDaily If you're using https://t.co/e5rnQ1Ff9H it's acting a bit wonky tonight. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. This has long been a data free zone. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rates, and potential complications. #lcsm |
| Dave Bjork @bjork5 Woohoo! @NarjustDumaMD 🙌 #LCSM |
| #LCSM Chat @lcsmchat @n8pennell Hello famous @people correspondent. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. In general, I have always argued that we need to show that we can be successful in approved populations before expanding more broadly. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat @CroixDenise Welcome! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. This has long been a data free zone. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rates, and potential complications. #lcsm |
| #LCSM Chat @lcsmchat @MimiProvenzano Hi Mimi #lcsm |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT |
| Stephen V Liu, MD @StephenVLiu RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @BrendonStilesMD We can't cover everything in one hour! I believe some #radonc advances were presented in the #STS conference on the same weekend as #WCLC20. #LCSM |
| Brendon Stiles @BrendonStilesMD T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. In general, I have always argued that we need to show that we can be successful in approved populations before expanding more broadly. #lcsm |
| #LCSM Chat @lcsmchat @Kamacintosh Hi Kim #lcsm |
| mimiprovenzano @MimiProvenzano @lcsmchat Hey Deanna! #lcsm |
| Jill Feldman @jillfeldman4 T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of the time it's not cancer. Not easy to tell someone (who knows nothing about #lungcancer) that a small nodule was found but wait 6 mths to scan #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm |
| #LCSM Chat @lcsmchat RT @coffeemommy: @JFreemanDaily If you're using https://t.co/e5rnQ1Ff9H it's acting a bit wonky tonight. #lcsm |
 | Inspire @InspireIsHealth RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. This has long been a data free zone. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rates, and potential complications. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @BrendonStilesMD Since never smoker lung cancer is on the rise, methinks it is definitely time to look at including other risk factors in the screening criteria. Family history is a big one. But also we seem to be seeing a helluva lot of potentially pollution-induced cancers. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. In general, I have always argued that we need to show that we can be successful in approved populations before expanding more broadly. #lcsm |
| kristen kimball @KimballKristen @JFreemanDaily It does seem more difficult tonight! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of the time it's not cancer. Not easy to tell someone (who knows nothing about #lungcancer) that a small nodule was found but wait 6 mths to scan #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
| #LCSM Chat @lcsmchat RT @coffeemommy: @BrendonStilesMD Since never smoker lung cancer is on the rise, methinks it is definitely time to look at including other risk factors in the screening criteria. Family history is a big one. But also we seem to be seeing a helluva lot of potentially pollution-induced cancers. #lcsm |
| Inspire @InspireIsHealth Hello to the #lcsm community, John Novack grateful here on behalf of Inspire, to listen and learn. |
| Brendon Stiles @BrendonStilesMD T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of the time it's not cancer. Not easy to tell someone (who knows nothing about #lungcancer) that a small nodule was found but wait 6 mths to scan #LCSM |
| Lillian Leigh @ProjectBreath T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a fantastic start to us having data to justify screening in never smokers. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI |
 | Kimberley H Geissler @khgeissler @BrendonStilesMD T1. Is there any evidence of higher risk in eg, never smoker daughter of never smoker with LC? #lcsm |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers in Taiwan. But it will be hard to show a similar impact in a region with a lower incidence. Balance benefit with cost and risks. #LCSM |
| Brendon Stiles @BrendonStilesMD T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0 |
| Janet Freeman-Daily @JFreemanDaily RT @coffeemommy: @BrendonStilesMD Since never smoker lung cancer is on the rise, methinks it is definitely time to look at including other risk factors in the screening criteria. Family history is a big one. But also we seem to be seeing a helluva lot of potentially pollution-induced cancers. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @ProjectBreath: T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a fantastic start to us having data to justify screening in never smokers. #LCSM |
 | Deepti Behl, M.D. @deeptibehl1 @JFreemanDaily Yes me too, feel like not seeing it all #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. Unclear how much that translates outside Asia. #lcsm |
 | Jamie Holloway, PhD @jamienholloway Jumping in late to the #LCSM chat, eager to hear more from world lung! |
| Christine Qiong Wu @wi_qiong @BrendonStilesMD Yes, >10% of us are never smokers. #LCSM |
| Jill Feldman @jillfeldman4 T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, radon, etc. It's ridiculous that current guidelines only include smoking history and age - it's an incomplete way & misses a lot of people #LCSM |
| Brendon Stiles @BrendonStilesMD T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
| #LCSM Chat @lcsmchat @deeptibehl1 @EricBernicker Welcome! Remember to include #lcsm in your tweets so we can see them during the chat. |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @ProjectBreath Totally agree #lcsm |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn |
 | Sue McCullough @SueMcCu30398663 #LCSM I think I will just watch the tweets for a while, I much rather talking, I just don't type fast. |
 | Flemming Rasmussen @fgrazz @LungCancerFaces @lcsmchat and @fgrazz from Halifax listening in #lcsm |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @BrendonStilesMD @JFreemanDaily If you're just now getting "sick" of it, you are far more robust than I am. Thinking I started to crack from hug withdrawl about 3 weeks in last Spring. Looking forward to post-vaccine hugging before the end of the year. #lcsm |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0 |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn |
| #LCSM Chat @lcsmchat @teaminspire Hi John #lcsm |
| Brendon Stiles @BrendonStilesMD T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.co/x9hPPhI5pa Is there likely an inheritable risk of lung cancer... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn |
| Lillian Leigh @ProjectBreath @jillfeldman4 That's a really good point @jillfeldman4. Do you think that this challenge would reduce over time when there's more understanding in the general public about #lungcancer as well as other lung disease? #lcsm |
| #LCSM Chat @lcsmchat RT @ProjectBreath: T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a fantastic start to us having data to justify screening in never smokers. #LCSM |
| #LCSM Chat @lcsmchat RT @khgeissler: @BrendonStilesMD T1. Is there any evidence of higher risk in eg, never smoker daughter of never smoker with LC? #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers in Taiwan. But it will be hard to show a similar impact in a region with a lower incidence. Balance benefit with cost and risks. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0 |
| #LCSM Chat @lcsmchat RT @n8pennell: T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. Unclear how much that translates outside Asia. #lcsm |
| #LCSM Chat @lcsmchat @jamienholloway Thanks for joining! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM |
| Brendon Stiles @BrendonStilesMD @coffeemommy @JFreemanDaily I am going to hug the heck out of many people. It is going to be uncomfortable. Apologizing in advance. #lcsm |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, radon, etc. It's ridiculous that current guidelines only include smoking history and age - it's an incomplete way & misses a lot of people #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
 | KRASKickers @KRASKickers @JFreemanDaily #LCSM chat Hey all - I am fashionably late this evening ./ This is Terri |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn |
 | Nicole Rossi MD Oncologist @NicoleRossiOnco RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
| Nicole Rossi MD Oncologist @NicoleRossiOnco Me too |
| Janet Freeman-Daily @JFreemanDaily RT @ProjectBreath: T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a fantastic start to us having data to justify screening in never smokers. #LCSM |
| #LCSM Chat @lcsmchat @SueMcCu30398663 We were all newbies once. You’ll get the hang of it. I promise. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers in Taiwan. But it will be hard to show a similar impact in a region with a lower incidence. Balance benefit with cost and risks. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0 |
| Brendon Stiles @BrendonStilesMD @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We'll get there eventually. #lcsm |
| Lillian Leigh @ProjectBreath RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.co/x9hPPhI5pa Is there likely an inheritable risk of lung cancer... #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. Unclear how much that translates outside Asia. #lcsm |
| #LCSM Chat @lcsmchat RT @ProjectBreath: @jillfeldman4 That's a really good point @jillfeldman4. Do you think that this challenge would reduce over time when there's more understanding in the general public about #lungcancer as well as other lung disease? #lcsm |
| Jill Feldman @jillfeldman4 @ProjectBreath Educating people is key. I feel like once it's explained in a way that people can understand it's less anxiety provoking, but there are still those who won't be able to compartmentalize and there is no easy way to do a lung biopsy! #LCSM |
| Eric Bernicker @EricBernicker @jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbers are awful--expanding to other populations will be difficult #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM |
| Stephen V Liu, MD @StephenVLiu RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, radon, etc. It's ridiculous that current guidelines only include smoking history and age - it's an incomplete way & misses a lot of people #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
| Brendon Stiles @BrendonStilesMD Another of my all time favorites! Love seeing your here! #lcsm |
| #LCSM Chat @lcsmchat @kRasKickers @JFreemanDaily Hey Terri! #lcsm |
| Jill Feldman @jillfeldman4 RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We'll get there eventually. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @ProjectBreath Educating people is key. I feel like once it's explained in a way that people can understand it's less anxiety provoking, but there are still those who won't be able to compartmentalize and there is no easy way to do a lung biopsy! #LCSM |
| Jill Feldman @jillfeldman4 RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.co/x9hPPhI5pa Is there likely an inheritable risk of lung cancer... #lcsm |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @jillfeldman4 Indeed the idea of watchful waiting is hard. Hoping that there will be other ways to intelligently screen high risk populations (across all cancers) moving forward. Liquid biopsies as screening aren't there yet but have potential. #lcsm |
| #LCSM Chat @lcsmchat RT @EricBernicker: @jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbers are awful--expanding to other populations will be difficult #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.co/x9hPPhI5pa Is there likely an inheritable risk of lung cancer... #lcsm |
 | Chief Judith Roney-Carroll(Ret.)REDSTORMRISE^2022 @cbpd800 RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM |
| #LCSM Chat @lcsmchat RT @coffeemommy: @jillfeldman4 Indeed the idea of watchful waiting is hard. Hoping that there will be other ways to intelligently screen high risk populations (across all cancers) moving forward. Liquid biopsies as screening aren't there yet but have potential. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ProjectBreath: @jillfeldman4 That's a really good point @jillfeldman4. Do you think that this challenge would reduce over time when there's more understanding in the general public about #lungcancer as well as other lung disease? #lcsm |
| Eric Bernicker @EricBernicker @BrendonStilesMD @StephenVLiu I am hopeful that the increasing recognition on the need for environmental justice and pollution will lead to this being explored more thoroughly #LCSM |
 | Ronald Clarke @RonaldClarke RT @StephenVLiu: #ASCO20 Potential role of AXL in mediating acquired TKI resistance across fusion positive NSCLC (#ALK, #ROS1, #RET) and adding an AXL inhibitor to the original TKI was effective. Potential for combinations to delay or overcome TKI acquired resistance? #LCSM #OncoAlert https://t.co/JB2ZEh28FA |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screening strategies in the not too distant future. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM |
| Inspire @InspireIsHealth RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We'll get there eventually. #lcsm |
| Brendon Stiles @BrendonStilesMD T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim, let's increase screening rates in eligible patients! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: @ProjectBreath Educating people is key. I feel like once it's explained in a way that people can understand it's less anxiety provoking, but there are still those who won't be able to compartmentalize and there is no easy way to do a lung biopsy! #LCSM |
| #LCSM Chat @lcsmchat I see you @SeastedtMD! Thanks for joining us. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbers are awful--expanding to other populations will be difficult #LCSM |
| kristen kimball @KimballKristen T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died of EGFR+ LC. Hoping for biomarker or other breakthroughs for them & all ppl #lcsm |
| Jill Feldman @jillfeldman4 @coffeemommy The Holy Grail of early detection! #LCSM |
| Laura Greco @lgreco_ny @StephenVLiu @BrendonStilesMD T1: I think this will be a game changer. #LCSM |
| Inspire @InspireIsHealth RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Definitely something to look forward to in the future #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD @StephenVLiu I am hopeful that the increasing recognition on the need for environmental justice and pollution will lead to this being explored more thoroughly #LCSM |
| Brendon Stiles @BrendonStilesMD T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @coffeemommy: @jillfeldman4 Indeed the idea of watchful waiting is hard. Hoping that there will be other ways to intelligently screen high risk populations (across all cancers) moving forward. Liquid biopsies as screening aren't there yet but have potential. #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screening strategies in the not too distant future. #LCSM |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: |
| Brendon Stiles @BrendonStilesMD @MattSmeltzer Dramatically is my guess! #lcsm |
 | Gabriela Candás @gbc02 RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim, let's increase screening rates in eligible patients! #lcsm |
| #LCSM Chat @lcsmchat RT @KimballKristen: T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died of EGFR+ LC. Hoping for biomarker or other breakthroughs for them & all ppl #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screening strategies in the not too distant future. #LCSM |
| kristen kimball @KimballKristen @StephenVLiu @BrendonStilesMD Yes, hopping for this! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @DrRiyazShah: |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim, let's increase screening rates in eligible patients! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @KimballKristen: T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died of EGFR+ LC. Hoping for biomarker or other breakthroughs for them & all ppl #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: @coffeemommy The Holy Grail of early detection! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Definitely something to look forward to in the future #LCSM |
| #LCSM Chat @lcsmchat #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #Test #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Tough target, long time coming. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #Test #LCSM |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatment. Use in the first line will need to be combinations unless we can further in which the population that get long-term benefit. #LCSM |
| Jill Feldman @jillfeldman4 @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not too much to ask for :) #LCSM |
| KRASKickers @KRASKickers RT @JFreemanDaily: @watchyourcharts @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can read tonight's topic questions here: https://t.co/g6Dul2e8Mw |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @jillfeldman4 I simply cannot see/hear/read that phrase without busting into some quotable Monty Python quotes "It's just a flesh wound..." #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Reinforces the need for comprehensive molecular testing #NGS #LCSM |
| Eric Bernicker @EricBernicker @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for such a long time. Very exciting #LCSM |
| Brendon Stiles @BrendonStilesMD T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.co/Qw2G4o4Dli |
| #LCSM Chat @lcsmchat I see you @CCuadra8! Thanks for joining us. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @StephenVLiu: @BrendonStilesMD T2: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatment. Use in the first line will need to be combinations unless we can further in which the population that get long-term benefit. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #Test #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first line yet. But promising first step that will lead to better treatments soon #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Tough target, long time coming. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Tough target, long time coming. #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @BrendonStilesMD T2: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatment. Use in the first line will need to be combinations unless we can further in which the population that get long-term benefit. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T2: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatment. Use in the first line will need to be combinations unless we can further in which the population that get long-term benefit. #LCSM |
| Brendon Stiles @BrendonStilesMD T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not too much to ask for :) #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not too much to ask for :) #LCSM |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.co/Qw2G4o4Dli |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Reinforces the need for comprehensive molecular testing #NGS #LCSM |
 | Hossen Mahmud, MD @DrHMahmudMD RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.co/Qw2G4o4Dli |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @jillfeldman4: @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not too much to ask for :) #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for such a long time. Very exciting #LCSM |
| Brendon Stiles @BrendonStilesMD @EricBernicker I am so on the look out for a Wonka ticket! #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so till we see data in the 1L setting, we should use these in 2L #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first line yet. But promising first step that will lead to better treatments soon #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. And here are the results: T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: T2: |
| Stephen V Liu, MD @StephenVLiu @BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be exceptionally durable. I’m not willing to trade that for the targeted agents just yet. So the first line setting for me is still immunotherapy-based. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so till we see data in the 1L setting, we should use these in 2L #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @BrendonStilesMD T2: @BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be exceptionally durable. I’m not willing to trade that for the targeted agents just yet. So the first line setting for me is still immunotherapy-based. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @DrRiyazShah What is the national NGS model? #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @DrRiyazShah What is the national NGS model? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.co/Qw2G4o4Dli |
| Brendon Stiles @BrendonStilesMD T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for such a long time. Very exciting #LCSM |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomarker testing as a STANDARD at diagnosis. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first line yet. But promising first step that will lead to better treatments soon #LCSM |
| kristen kimball @KimballKristen @StephenVLiu @BrendonStilesMD Hoping now, will be hopping w joy when it happens #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. And here are the results: T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz |
| Brendon Stiles @BrendonStilesMD T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbloong https://t.co/lENIV32HJ0 |
| #LCSM Chat @lcsmchat I see you @ErikaHlavacek! Thanks for joining. #lcsm |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| Lillian Leigh @ProjectBreath T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS is so high in lung adenocarcinoma! #LCSM https://t.co/TgN14FSzrY |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM |
| kristen kimball @KimballKristen @lgreco_ny @StephenVLiu @BrendonStilesMD T1 yes or will #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @DrRiyazShah: T2: |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. Happy to be able to join the #lcsm discussion. #PatientsFirst |
| Brendon Stiles @BrendonStilesMD T2. Important to remember that these are pretreated patients. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so till we see data in the 1L setting, we should use these in 2L #LCSM |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD Hi Tim! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD T2: @BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be exceptionally durable. I’m not willing to trade that for the targeted agents just yet. So the first line setting for me is still immunotherapy-based. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @ProjectBreath: T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS is so high in lung adenocarcinoma! #LCSM https://t.co/TgN14FSzrY |
| Sue McCullough @SueMcCu30398663 I have at least updated my profile. #LCSM |
| Henning Willers, MD @HenningWillers @BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be needed #lcsm |
| #LCSM Chat @lcsmchat @jillfeldman4 @CCuadra8 If someone “likes” a tweet, I can see it. #lcsm |
 | Karma Macgregor @KarmaMacgregor RT @JillHW: Terrific news! On behalf of Canadians affected by lung cancer, thank you. #lcsm |
| KRASKickers @KRASKickers RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #Test #LCSM |
| #LCSM Chat @lcsmchat Hi @JohnLPender! Hope you’re doing OK. #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy, @BrendonStilesMD! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @coffeemommy: @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomarker testing as a STANDARD at diagnosis. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DrRiyazShah: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbloong https://t.co/lENIV32HJ0 |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments, quite distinct from EGFR/ALK/ROS. I think 37% is pretty exciting! #LCSM |
| #LCSM Chat @lcsmchat RT @coffeemommy: @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomarker testing as a STANDARD at diagnosis. #lcsm |
| Brendon Stiles @BrendonStilesMD T3 coming soon! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @coffeemommy: @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomarker testing as a STANDARD at diagnosis. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbloong https://t.co/lENIV32HJ0 |
| #LCSM Chat @lcsmchat RT @ProjectBreath: T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS is so high in lung adenocarcinoma! #LCSM https://t.co/TgN14FSzrY |
| Janet Freeman-Daily @JFreemanDaily RT @ProjectBreath: T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS is so high in lung adenocarcinoma! #LCSM https://t.co/TgN14FSzrY |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #hope #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @coffeemommy @JFreemanDaily @BrendonStilesMD Agree #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Important to remember that these are pretreated patients. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Important to remember that these are pretreated patients. #lcsm |
| #LCSM Chat @lcsmchat @SueMcCu30398663 Love the pic! #lcsm |
| Brendon Stiles @BrendonStilesMD T3. What is new in mesothelioma and small cell lung cancer? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be needed #lcsm |
| Lillian Leigh @ProjectBreath @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday Can you please expand on this @CharuAggarwalMD? I'm interested to hear more #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be needed #lcsm |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: |
| Lillian Leigh @ProjectBreath RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj |
| Brendon Stiles @BrendonStilesMD RT @ProjectBreath: @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday Can you please expand on this @CharuAggarwalMD? I'm interested to hear more #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2d that! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments, quite distinct from EGFR/ALK/ROS. I think 37% is pretty exciting! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @DrRiyazShah: |
| Jill Feldman @jillfeldman4 T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered un-targetable. #LCSM |
| Deepti Behl, M.D. @deeptibehl1 @DrRiyazShah Blood 🩸 based testing showing promise #lcsm |
| Eric Bernicker @EricBernicker @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could potentially benefit is immense. Many years of effort and study and prayer on that waterfall plot... #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj |
| KRASKickers @KRASKickers RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments, quite distinct from EGFR/ALK/ROS. I think 37% is pretty exciting! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. What is new in mesothelioma and small cell lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @ProjectBreath: @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday Can you please expand on this @CharuAggarwalMD? I'm interested to hear more #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Mesothelioma and small cell are too often left behind. Both terrible diseases. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. What is new in mesothelioma and small cell lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered un-targetable. #LCSM |
 | Erika Hlavacek @ErikaHlavacek so true with unmet need! |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @jillfeldman4 A game changer #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could potentially benefit is immense. Many years of effort and study and prayer on that waterfall plot... #LCSM |
| Brendon Stiles @BrendonStilesMD T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From @DrRiyazShah https://t.co/ZqNPtLVmNv |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered un-targetable. #LCSM |
| #LCSM Chat @lcsmchat RT @deeptibehl1: @DrRiyazShah Blood 🩸 based testing showing promise #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @EricBernicker: @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could potentially benefit is immense. Many years of effort and study and prayer on that waterfall plot... #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Mesothelioma and small cell are too often left behind. Both terrible diseases. #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD @HemOncToday @molina_arcas Naturally we are working on combining KRAS G12C inhibition with #radiotherapy #radonc #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From @DrRiyazShah https://t.co/ZqNPtLVmNv |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD @HemOncToday @molina_arcas Naturally we are working on combining KRAS G12C inhibition with #radiotherapy #radonc #lcsm |
| Sue McCullough @SueMcCu30398663 #LCSM Lillian,I think next time I need you socially distant showing me how to 'be apart of the discussions.' |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could potentially benefit is immense. Many years of effort and study and prayer on that waterfall plot... #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas #lcsm https://t.co/KflK3kTovA |
 | Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @JFreemanDaily: @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @ProjectBreath @HenningWillers @BrendonStilesMD @HemOncToday Unlike single oncogene driven tumors, KRAS MT tumors often have other co-occuring mutations and complex tumor microenviroment interplay may reduce sensitivity to TKIs #LCSM |
| Eric Bernicker @EricBernicker @BrendonStilesMD Significant benefit of immunotherapy in Meso and exciting clarification of molecular sub-classification in small cell that could really facilitate better trials #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Still a long way to go for this terrible disease, but Nivolumab improved overall survival, specifically for the epithelioid subtype. #lcsm https://t.co/9Upt4PEf2F |
| Dave Bjork @bjork5 This is amazing! #research #liquidbiopsy #LCSM |
| #LCSM Chat @lcsmchat Hey @Tricia_Braun! Hope you’re doing well. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Still have to determine how best to handle first line treatment and to identify predictors of response. From @DrJNaidoo #lcsm https://t.co/8XdDcY2RPA |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: T2: |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @ProjectBreath @HenningWillers @BrendonStilesMD @HemOncToday Unlike single oncogene driven tumors, KRAS MT tumors often have other co-occuring mutations and complex tumor microenviroment interplay may reduce sensitivity to TKIs #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD Significant benefit of immunotherapy in Meso and exciting clarification of molecular sub-classification in small cell that could really facilitate better trials #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Still a long way to go for this terrible disease, but Nivolumab improved overall survival, specifically for the epithelioid subtype. #lcsm https://t.co/9Upt4PEf2F |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Still have to determine how best to handle first line treatment and to identify predictors of response. From @DrJNaidoo #lcsm https://t.co/8XdDcY2RPA |
| Dave Bjork @bjork5 This! 👇👇👇 #lcsm @kRasKickers |
| Sue McCullough @SueMcCu30398663 #LCSM the photo, not mine oneis my cat Tess. |
| Brendon Stiles @BrendonStilesMD T3. Several great talks on small cell lung cancer as well. #lcsm From @BenLok https://t.co/GXtY9ljAOX |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Awful #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung cancer. #lcsm https://t.co/se4kFIxJmE |
 | Matt Galsky @MattGalsky RT @DDoroshow: Kudos to @SheenaBhallaMD, representing our #CCOS research group @AACR today in her talk on pandemic-related care disruption for people with #lungcancer. @TischCancer @DanaFarber @MattGalsky @DrChoueiri @ZiadBakouny @dr_aschmidt #lcsm |
| Jill Feldman @jillfeldman4 T3 I thought the data on the high rates of pathologic germline mutations in #SCLC were very interesting! 67%! Interested in seeing more studies #LCSM |
| Christine Qiong Wu @wi_qiong @DrRiyazShah How far is blood and urine breath... for testing lung cancer? #LCSM @DrRiyazShah |
 | Linnea Olson @1111linno T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some progress. #lcsm |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung cancer. #lcsm https://t.co/se4kFIxJmE |
 | Tricia Braun @Tricia_Braun @lcsmchat I am, thanks! Hope you all are well, too! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Several great talks on small cell lung cancer as well. #lcsm From @BenLok https://t.co/GXtY9ljAOX |
| Dave Bjork @bjork5 💯 #lcsm #PrecisionMedicine |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung cancer. #lcsm https://t.co/se4kFIxJmE |
| Brendon Stiles @BrendonStilesMD T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co/4mR8Kuc8tt #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T3 I thought the data on the high rates of pathologic germline mutations in #SCLC were very interesting! 67%! Interested in seeing more studies #LCSM |
| #LCSM Chat @lcsmchat RT @wi_qiong: @DrRiyazShah How far is blood and urine breath... for testing lung cancer? #LCSM @DrRiyazShah |
| #LCSM Chat @lcsmchat RT @1111linno: T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some progress. #lcsm |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: |
| Brendon Stiles @BrendonStilesMD T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co/4mR8Kuc8tt #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| Tricia Braun @Tricia_Braun RT @StephenVLiu: @BrendonStilesMD T1: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screening strategies in the not too distant future. #LCSM |
| Linnea Olson @1111linno T3 But never enough ;) #lcsm |
| Eric Bernicker @EricBernicker @BrendonStilesMD @LaurenByersMD Agree this is very exciting and valuable work #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From @DrRiyazShah https://t.co/ZqNPtLVmNv |
| Dave Bjork @bjork5 @n8pennell This is so promising! 🙏🏽 #lcsm #kras #PrecisionMedicine |
| Brendon Stiles @BrendonStilesMD Where is @jillfeldman4? T4 coming next! #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. How can we make clinical trials better and more patient centric? #lcsm |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @1111linno YES! And in large part to your (and many others') willingness to contribute to research. #lcsm Thank you, my friend. (Wish I could thank you with a vaccine 💗 and a hug!) |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. How can we make clinical trials better and more patient centric? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #LiquidBiopsy #lcsm |
| Dave Bjork @bjork5 Again, this! 👇 #LCSM #research |
 | Sara Whitlock @sjwhitlock T4. Early involvement!!!#LCSM |
| Brendon Stiles @BrendonStilesMD T4. Key to think about the patient perspective from the very beginning of trial design. #lcsm |
| Linnea Olson @1111linno T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Key to think about the patient perspective from the very beginning of trial design. #lcsm |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Early involvement!!!#LCSM |
| #LCSM Chat @lcsmchat RT @1111linno: T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Need to work hard to get past surgical therapy. #lcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @1111linno: T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm |
| Brendon Stiles @BrendonStilesMD T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm https://t.co/mSghvVJZ8B |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Need to work hard to get past surgical therapy. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm https://t.co/mSghvVJZ8B |
 | Mark B In SD @MomsOopsBaby RT @1111linno: T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some progress. #lcsm |
| Sara Whitlock @sjwhitlock T4. Jill has said it best. What is important to the researcher not always same to the patient. #LCSM |
| Jill Feldman @jillfeldman4 T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| Brendon Stiles @BrendonStilesMD T4. We should be able to expand eligibility. #lcsm https://t.co/HhmFahchcj |
| Lillian Leigh @ProjectBreath T4. This 👇. That's how! @jillfeldman4 #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @jillfeldman4 Well said #lcsm |
| Sara Whitlock @sjwhitlock T4. Expand inclusion criteria #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| Dave Bjork @bjork5 @HemOncToday @IASLC @sloan_kettering @MMarmarelis @Penn Impressive! #lcsm @BrendonStilesMD @CharuAggarwalMD |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Jill has said it best. What is important to the researcher not always same to the patient. #LCSM |
| Henning Willers, MD @HenningWillers RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. We should be able to expand eligibility. #lcsm https://t.co/HhmFahchcj |
| Jill Feldman @jillfeldman4 T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but only patients and caregivers are impacted by every decision made from the beginning and throughout the entire process. Yet, not always included! #LCSM https://t.co/nwPAF1c7u1 |
| #LCSM Chat @lcsmchat RT @ProjectBreath: T4. This 👇. That's how! @jillfeldman4 #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Expand inclusion criteria #LCSM |
| Sue McCullough @SueMcCu30398663 #LCSM Advocates as apart of the trial design! |
| mimiprovenzano @MimiProvenzano RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but only patients and caregivers are impacted by every decision made from the beginning and throughout the entire process. Yet, not always included! #LCSM https://t.co/nwPAF1c7u1 |
| Brendon Stiles @BrendonStilesMD T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33 |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung cancer. #lcsm https://t.co/se4kFIxJmE |
| Linnea Olson @1111linno T4 I had to pay out of pocket costs today for drug to combat side effects of clinical trial drug. Why would sponsor not pick up cost? #lcsm |
| #LCSM Chat @lcsmchat RT @SueMcCu30398663: #LCSM Advocates as apart of the trial design! |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @SueMcCu30398663 Oh Sue great pic #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33 |
| #LCSM Chat @lcsmchat RT @1111linno: T4 I had to pay out of pocket costs today for drug to combat side effects of clinical trial drug. Why would sponsor not pick up cost? #lcsm |
 | Jonathan Spicer MD PhD @DoctorJSpicer @BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas And obviously with #surgery. Doesn’t prehabilitation and pill before going for curative surgery sound good? So many opportunities to learn patterns of resistance and confirm immunological effects of this targeted therapy either alone or combined with other agents #lcsm #tssmn |
| Lillian Leigh @ProjectBreath RT @BrendonStilesMD: T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33 |
 | Herbert Loong @herbloong RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbloong https://t.co/lENIV32HJ0 |
 | Tim Broyle, MD @BroyleTim RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but only patients and caregivers are impacted by every decision made from the beginning and throughout the entire process. Yet, not always included! #LCSM https://t.co/nwPAF1c7u1 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Go @1111linno! #lcsm |
| Linnea Olson @1111linno T4 Talk to patients but talk to the RIGHT patients. Those who have participated in trials. And or been excluded from participation. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Good to discuss and prioritize endpoints important to patients – survival, recurrence, quality of life. It is what is important to them, not so much us. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DrRiyazShah: |
| mimiprovenzano @MimiProvenzano RT @TimAllenMDJD: Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm |
| Peggy Dennis @peggyddennis T4 - Expand to driver mutations across different cancer types. I.e. breast/ lung/gastric. Lots of data #lcsm |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @BrendonStilesMD Rhetorical question for this crowd. Perhaps a better question is HOW do we take the obvious answer of "involve patients!" and share it in a way to influence the larger healthcare/cancercare/research ecosystem? #lcsm #hcldr |
| LungCancer.net @LungCancer_HU RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| Dave Bjork @bjork5 @1111linno T4 great timing for your entrance! #lcsm #patients 💯💯💯💯 |
| Brendon Stiles @BrendonStilesMD T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From @ProjectBreath https://t.co/j6eDKPc4sV |
| Lillian Leigh @ProjectBreath @BrendonStilesMD @IASLC Yes, thank you to @IASLC for taking the lead. Same with @globalungcancer as well. We desperately need to change the status quo! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co/4mR8Kuc8tt #lcsm |
 | benjamin wu @benjaminwumd RT @DrRiyazShah: |
| Jill Feldman @jillfeldman4 T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and doesn't adress the fact that people in under resourced communities don't participate because they aren't aware and/or not asked! #LCSM https://t.co/rRfazYT5yk |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| Lillian Leigh @ProjectBreath RT @BrendonStilesMD: T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From @ProjectBreath https://t.co/j6eDKPc4sV |
| Sara Whitlock @sjwhitlock T4. Also improve PROs. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @DrRiyazShah: |
| Brendon Stiles @BrendonStilesMD T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but only patients and caregivers are impacted by every decision made from the beginning and throughout the entire process. Yet, not always included! #LCSM https://t.co/nwPAF1c7u1 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co/4mR8Kuc8tt #lcsm |
| Jonathan Spicer MD PhD @DoctorJSpicer @BrendonStilesMD More changed for the better of mesothelioma patients in the last year than in the prior 20! Can’t wait to see how this fits with potentially operable patients. #lcsm #tssmn |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @SueMcCu30398663: #LCSM Advocates as apart of the trial design! |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @BrendonStilesMD @LaurenByersMD Agree this is very exciting and valuable work #LCSM |
| Brendon Stiles @BrendonStilesMD T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https://t.co/FETEC3m3zi |
| #LCSM Chat @lcsmchat RT @DoctorJSpicer: @BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas And obviously with #surgery. Doesn’t prehabilitation and pill before going for curative surgery sound good? So many opportunities to learn patterns of resistance and confirm immunological effects of this targeted therapy either alone or combined with other agents #lcsm #tssmn |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies. #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T4 Talk to patients but talk to the RIGHT patients. Those who have participated in trials. And or been excluded from participation. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Good to discuss and prioritize endpoints important to patients – survival, recurrence, quality of life. It is what is important to them, not so much us. #lcsm |
| Dave Bjork @bjork5 @jillfeldman4 Volunteers are VIPs #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. How can we make clinical trials better and more patient centric? #lcsm |
| #LCSM Chat @lcsmchat RT @peggyddennis: T4 - Expand to driver mutations across different cancer types. I.e. breast/ lung/gastric. Lots of data #lcsm |
| #LCSM Chat @lcsmchat RT @coffeemommy: @BrendonStilesMD Rhetorical question for this crowd. Perhaps a better question is HOW do we take the obvious answer of "involve patients!" and share it in a way to influence the larger healthcare/cancercare/research ecosystem? #lcsm #hcldr |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From @ProjectBreath https://t.co/j6eDKPc4sV |
| #LCSM Chat @lcsmchat RT @ProjectBreath: @BrendonStilesMD @IASLC Yes, thank you to @IASLC for taking the lead. Same with @globalungcancer as well. We desperately need to change the status quo! #LCSM |
| Brendon Stiles @BrendonStilesMD @coffeemommy Definitely deserving of an in depth discussion. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD We MUST continue to address! #lcsm |
| Lillian Leigh @ProjectBreath RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https://t.co/FETEC3m3zi |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and doesn't adress the fact that people in under resourced communities don't participate because they aren't aware and/or not asked! #LCSM https://t.co/rRfazYT5yk |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: T4: |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T4. Also improve PROs. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DoctorJSpicer: @BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas And obviously with #surgery. Doesn’t prehabilitation and pill before going for curative surgery sound good? So many opportunities to learn patterns of resistance and confirm immunological effects of this targeted therapy either alone or combined with other agents #lcsm #tssmn |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI |
| #LCSM Chat @lcsmchat RT @DoctorJSpicer: @BrendonStilesMD More changed for the better of mesothelioma patients in the last year than in the prior 20! Can’t wait to see how this fits with potentially operable patients. #lcsm #tssmn |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https://t.co/FETEC3m3zi |
| Brendon Stiles @BrendonStilesMD RT @ProjectBreath: @BrendonStilesMD @IASLC Yes, thank you to @IASLC for taking the lead. Same with @globalungcancer as well. We desperately need to change the status quo! #LCSM |
| #LCSM Chat @lcsmchat RT @bjork5: @jillfeldman4 Volunteers are VIPs #lcsm |
| Lillian Leigh @ProjectBreath RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and doesn't adress the fact that people in under resourced communities don't participate because they aren't aware and/or not asked! #LCSM https://t.co/rRfazYT5yk |
| Linnea Olson @1111linno T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, physical. #lcsm |
| Brendon Stiles @BrendonStilesMD This.... #lcsm |
| Christine Qiong Wu @wi_qiong RT @1111linno: T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm |
 | Dr. Amy C. Moore @acmoorephd Sorry I'm late to the party #LCSM |
| #LCSM Chat @lcsmchat RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, physical. #lcsm |
| Jill Feldman @jillfeldman4 T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be written to include those requirements, which means they will be in the protocol & so on. #LCSM |
| Matthew Smeltzer @MattSmeltzer RT @TimAllenMDJD: We MUST continue to address! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #QualityOfLife is too often overlooked or minimized. #lcsm |
| kristen kimball @KimballKristen @jillfeldman4 thank you for caregiver inclusion #lcsm |
| Dr. Amy C. Moore @acmoorephd RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo |
| Brendon Stiles @BrendonStilesMD Homestretch....T5 coming up. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @coffeemommy: @BrendonStilesMD Rhetorical question for this crowd. Perhaps a better question is HOW do we take the obvious answer of "involve patients!" and share it in a way to influence the larger healthcare/cancercare/research ecosystem? #lcsm #hcldr |
| Stacey Tinianov (she/her) MPH, BCPA @coffeemommy @jillfeldman4 So much this! 🎉 Across clinical trials, cancer care, supportive care and then across ALL of heath care. Designing "for" patients was so 2000s. We need to design WITH patients & their families. #lcsm #bcsm #crcsm #gyncsm #pancsm #cancerresearch #WorldCancerDay |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be written to include those requirements, which means they will be in the protocol & so on. #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: #QualityOfLife is too often overlooked or minimized. #lcsm |
| KRASKickers @KRASKickers RT @BrendonStilesMD: This.... #lcsm |
| Janet Freeman-Daily @JFreemanDaily T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate disparities in age, income, socioeconomic factors. #LCSM https://t.co/k6w69irIwB |
| Linnea Olson @1111linno T4 Change the language. Scratch noncompliant. And volunteer. I am not a fucking volunteer. Cancer chose me and I was desperate. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: We MUST continue to address! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #PatientsFirst #lcsm |
| #LCSM Chat @lcsmchat RT @coffeemommy: @jillfeldman4 So much this! 🎉 Across clinical trials, cancer care, supportive care and then across ALL of heath care. Designing "for" patients was so 2000s. We need to design WITH patients & their families. #lcsm #bcsm #crcsm #gyncsm #pancsm #cancerresearch #WorldCancerDay |
| Janet Freeman-Daily @JFreemanDaily RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, physical. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and doesn't adress the fact that people in under resourced communities don't participate because they aren't aware and/or not asked! #LCSM https://t.co/rRfazYT5yk |
| KRASKickers @KRASKickers RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https://t.co/FETEC3m3zi |
| Brendon Stiles @BrendonStilesMD T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD RT @JFreemanDaily: T4: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate disparities in age, income, socioeconomic factors. #LCSM https://t.co/k6w69irIwB |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: This.... #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be written to include those requirements, which means they will be in the protocol & so on. #LCSM |
| Matthew Smeltzer @MattSmeltzer Agree! Including selection of endpoints |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate disparities in age, income, socioeconomic factors. #LCSM https://t.co/k6w69irIwB |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: #QualityOfLife is too often overlooked or minimized. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T4 Change the language. Scratch noncompliant. And volunteer. I am not a fucking volunteer. Cancer chose me and I was desperate. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI |
| Dr. Amy C. Moore @acmoorephd As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| Inspire @InspireIsHealth RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| Lillian Leigh @ProjectBreath Taking this opportunity to acknowledge the wonderful work that many in Australia are doing in this space - @NicStraiton @cancer_K2A @CancerSPHERE @ACTA_org @hagsie @COSA_Surviv and so many more (please tag!) #LCSM |
| KRASKickers @KRASKickers RT @DrRiyazShah: T4: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DoctorJSpicer: @BrendonStilesMD More changed for the better of mesothelioma patients in the last year than in the prior 20! Can’t wait to see how this fits with potentially operable patients. #lcsm #tssmn |
| Tricia Braun @Tricia_Braun RT @lgreco_ny: On this #worldcancerday please remember all of the millions of cancer patients being denied the #CovidVaccine, which for them, is healthcare. #lcsm #bcsm |
| #LCSM Chat @lcsmchat RT @acmoorephd: As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC |
 | Hiroaki Akamatsu @AkamatsuHiroaki RT @CharuAggarwalMD: Capmatinib shows modest efficacy in patients with MET alterations treated with crizotinib Obj RR ~ 10% https://t.co/26XMRg4zYt @JTOonline #LCSM @METCrusaders @BeccaHeistMD @LeciaSequist @IbiayiMD https://t.co/x5zU9XEcrX |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, physical. #lcsm |
| #LCSM Chat @lcsmchat RT @ProjectBreath: Taking this opportunity to acknowledge the wonderful work that many in Australia are doing in this space - @NicStraiton @cancer_K2A @CancerSPHERE @ACTA_org @hagsie @COSA_Surviv and so many more (please tag!) #LCSM |
| Brendon Stiles @BrendonStilesMD T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ |
| Sara Whitlock @sjwhitlock T5. Must decentralize. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD @JFreemanDaily, #lcsm superstar! |
| Linnea Olson @1111linno T5 Bring it to the patient instead of expecting the patient to come to it. Telehealth but also informed local oncologists. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that matters to the PATIENT, tailored to the disease and type of treatment. #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @1111linno Need to learn patient perspective and commitment #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @coffeemommy: @jillfeldman4 So much this! 🎉 Across clinical trials, cancer care, supportive care and then across ALL of heath care. Designing "for" patients was so 2000s. We need to design WITH patients & their families. #lcsm #bcsm #crcsm #gyncsm #pancsm #cancerresearch #WorldCancerDay |
| Brendon Stiles @BrendonStilesMD T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20 https://t.co/qdBTUATm4R |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T5. Must decentralize. #LCSM |
| #LCSM Chat @lcsmchat RT @1111linno: T5 Bring it to the patient instead of expecting the patient to come to it. Telehealth but also informed local oncologists. #lcsm |
| Jill Feldman @jillfeldman4 T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and successful for them. As 'Who is NOT at the table' starting at R & D #LCSM |
| Hiroaki Akamatsu @AkamatsuHiroaki RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that matters to the PATIENT, tailored to the disease and type of treatment. #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @sjwhitlock: T5. Must decentralize. #LCSM |
| #LCSM Chat @lcsmchat RT @Kamacintosh: @1111linno Need to learn patient perspective and commitment #LCSM |
| Brendon Stiles @BrendonStilesMD T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #lcsm https://t.co/rFvclJ7SSn |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: #PatientsFirst #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20 https://t.co/qdBTUATm4R |
| Dave Bjork @bjork5 “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical #patients #clinicaltrials |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: T4: |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and successful for them. As 'Who is NOT at the table' starting at R & D #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #lcsm https://t.co/rFvclJ7SSn |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm |
| Jill Feldman @jillfeldman4 T4 The most important 'End Point' in a trial is the patient! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ProjectBreath: Taking this opportunity to acknowledge the wonderful work that many in Australia are doing in this space - @NicStraiton @cancer_K2A @CancerSPHERE @ACTA_org @hagsie @COSA_Surviv and so many more (please tag!) #LCSM |
| KRASKickers @KRASKickers RT @BrendonStilesMD: T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm https://t.co/mSghvVJZ8B |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ |
| LungCancer.net @LungCancer_HU RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm |
| KRASKickers @KRASKickers RT @bjork5: @n8pennell This is so promising! 🙏🏽 #lcsm #kras #PrecisionMedicine |
| Brendon Stiles @BrendonStilesMD T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 The most important 'End Point' in a trial is the patient! #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/month now and goes up annually #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: @JFreemanDaily, #lcsm superstar! |
| KRASKickers @KRASKickers RT @bjork5: 💯 #lcsm #PrecisionMedicine |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Rural and inner city patients. Racial minorities. LGBTQ. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @JFreemanDaily: @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that matters to the PATIENT, tailored to the disease and type of treatment. #LCSM |
| Eric Bernicker @EricBernicker @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds these days center on dealing with patients with no insurance or who are out of network or who have little family support #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| Jill Feldman @jillfeldman4 T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silence only perpetuates injustice. EVERYONE needs to do their part #LCSM |
 | virginia litle @vlitlemd T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/month now and goes up annually #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20 https://t.co/qdBTUATm4R |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be written to include those requirements, which means they will be in the protocol & so on. #LCSM |
| Linnea Olson @1111linno T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disparity. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Rural and inner city patients. Racial minorities. LGBTQ. #lcsm |
| #LCSM Chat @lcsmchat RT @EricBernicker: @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds these days center on dealing with patients with no insurance or who are out of network or who have little family support #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silence only perpetuates injustice. EVERYONE needs to do their part #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @DrRiyazShah: T4: |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and successful for them. As 'Who is NOT at the table' starting at R & D #LCSM |
| #LCSM Chat @lcsmchat RT @vlitlemd: T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @1111linno: T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disparity. #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disparity. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #lcsm https://t.co/rFvclJ7SSn |
| Jill Feldman @jillfeldman4 T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities and other groups also face disparities and barriers and need to be represented. #LCSM |
| Brendon Stiles @BrendonStilesMD T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems, insurance, and industry to seriously address. #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and successful for them. As 'Who is NOT at the table' starting at R & D #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical #patients #clinicaltrials |
| Jamie Holloway, PhD @jamienholloway @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the big protocols. It’s the sponsors. So glad they are listening more now, too. #lcsm |
 | Nirmal Raut @oncologician @BrendonStilesMD T5 .If there is no clinical trial in any country ,at least an expanded access should be mandatory #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities and other groups also face disparities and barriers and need to be represented. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #equity #NoStigma #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems, insurance, and industry to seriously address. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T4 The most important 'End Point' in a trial is the patient! #LCSM |
| Brendon Stiles @BrendonStilesMD T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: https://t.co/t1TGC42z7z |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/month now and goes up annually #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20 https://t.co/qdBTUATm4R |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Rural and inner city patients. Racial minorities. LGBTQ. #lcsm |
| Linnea Olson @1111linno T5 Lack of information/access is an issue but so is lack of resources. And fear. We must help each other out. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds these days center on dealing with patients with no insurance or who are out of network or who have little family support #LCSM |
| Lillian Leigh @ProjectBreath T5. Boy, there's so much that we can do... tweets only allow 280 characters! #LCSM |
| Brendon Stiles @BrendonStilesMD T5. And from @DevikaDasMD #lcsm https://t.co/ounoFtDJpr |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #lcsm https://t.co/rFvclJ7SSn |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silence only perpetuates injustice. EVERYONE needs to do their part #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical #patients #clinicaltrials |
| Janet Freeman-Daily @JFreemanDaily RT @vlitlemd: T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @1111linno: T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disparity. #lcsm |
 | Breast Advocate @BreastAdvocate RT @DrAttai: Re-addressing needs of cancer survivors during #COVID19 @DrN_CancerPCP et al in @JNCI_Now https://t.co/0ZZEOqohDB #bcsm #lcsm #gyncsm #btsm https://t.co/epBTiMDk23 |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities and other groups also face disparities and barriers and need to be represented. #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T5. This! I’d like to see a fraction of $ spent on drugs applied to getting every single eligible patient tested worldwide #LCSM |
| #LCSM Chat @lcsmchat RT @jamienholloway: @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the big protocols. It’s the sponsors. So glad they are listening more now, too. #lcsm |
| #LCSM Chat @lcsmchat RT @oncologician: @BrendonStilesMD T5 .If there is no clinical trial in any country ,at least an expanded access should be mandatory #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems, insurance, and industry to seriously address. #lcsm |
| Jill Feldman @jillfeldman4 T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and people trust people who are more like them. This should be written into funding! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Word #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jamienholloway: @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the big protocols. It’s the sponsors. So glad they are listening more now, too. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: https://t.co/t1TGC42z7z |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: @jillfeldman4 T4: |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @EricBernicker: @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds these days center on dealing with patients with no insurance or who are out of network or who have little family support #LCSM |
| #LCSM Chat @lcsmchat RT @1111linno: T5 Lack of information/access is an issue but so is lack of resources. And fear. We must help each other out. #lcsm |
| Brendon Stiles @BrendonStilesMD Undoubtedly a major challenge. I am going to jump all over it at @MontefioreNYC and @EinsteinMed #lcsm. This has to change. |
| Christine Qiong Wu @wi_qiong @TimAllenMDJD I can't agree more. #QualityOfLife is overlooked. #LCSM @TimAllenMDJD |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And from @DevikaDasMD #lcsm https://t.co/ounoFtDJpr |
| #LCSM Chat @lcsmchat RT @n8pennell: T5. This! I’d like to see a fraction of $ spent on drugs applied to getting every single eligible patient tested worldwide #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Walk the talk. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9 |
 | #StayHome @viralvideovlogs RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9 |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and people trust people who are more like them. This should be written into funding! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities and other groups also face disparities and barriers and need to be represented. #LCSM |
 | Dr. Catfish Black & Disabled (She/Her) @4WheelWorkOut #HighRiskNY |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems, insurance, and industry to seriously address. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Undoubtedly a major challenge. I am going to jump all over it at @MontefioreNYC and @EinsteinMed #lcsm. This has to change. |
| Dave Bjork @bjork5 Big issue. I don’t have the answer, but every lung cancer patient deserves access to genomic testing and latests treatments, academic or community setting. @OneOncology @FoundationATCG #lcsm #PrecisionMedicine |
| #LCSM Chat @lcsmchat RT @wi_qiong: @TimAllenMDJD I can't agree more. #QualityOfLife is overlooked. #LCSM @TimAllenMDJD |
 | emily.elswick @ElswickEmily RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9 |
| #LCSM Chat @lcsmchat RT @DrRiyazShah: |
| Sara Whitlock @sjwhitlock I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvantaged community members, providers, researchers, payers, regulatory agencies, pharmacy benefit managers, pharma, biotech, advocates, nonprofits ... #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvantaged community members, providers, researchers, payers, regulatory agencies, pharmacy benefit managers, pharma, biotech, advocates, nonprofits ... #LCSM |
| #LCSM Chat @lcsmchat RT @sjwhitlock: I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm |
 | Alicia C. Staley @stales RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical #patients #clinicaltrials |
| Lillian Leigh @ProjectBreath T5. Financial toxicity goes beyond health costs - consequential financial hardship impacts on family relationships, credit and debt, social security and other social hardship. #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @BrendonStilesMD @LauraMezquitaMD Delays and fear of going to hospital / can’t assess a patient by phone #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that matters to the PATIENT, tailored to the disease and type of treatment. #LCSM |
| Brendon Stiles @BrendonStilesMD Almost time to wind the chat down. This has been a great discussion. It is always therapeutic for me to see each of you here and to surround myself in this community. #lcsm |
| #LCSM Chat @lcsmchat RT @ProjectBreath: T5. Financial toxicity goes beyond health costs - consequential financial hardship impacts on family relationships, credit and debt, social security and other social hardship. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @wi_qiong: @TimAllenMDJD I can't agree more. #QualityOfLife is overlooked. #LCSM @TimAllenMDJD |
| Eric Bernicker @EricBernicker @sjwhitlock And are not aware that they are missing out on key information #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Almost time to wind the chat down. This has been a great discussion. It is always therapeutic for me to see each of you here and to surround myself in this community. #lcsm |
| Brendon Stiles @BrendonStilesMD This is shocking indeed. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @n8pennell I'd love to see the money that's currently spent on creating new "get biomarker testing!" websites applied to increasing provider education on the ground. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and people trust people who are more like them. This should be written into funding! #LCSM |
| Jill Feldman @jillfeldman4 T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of people with #lungcancer because of disparities Everyone below the water in this graph! #LCSM https://t.co/B3nYNnsnUq |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @n8pennell I'd love to see the money that's currently spent on creating new "get biomarker testing!" websites applied to increasing provider education on the ground. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of people with #lungcancer because of disparities Everyone below the water in this graph! #LCSM https://t.co/B3nYNnsnUq |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of people with #lungcancer because of disparities Everyone below the water in this graph! #LCSM https://t.co/B3nYNnsnUq |
| Lillian Leigh @ProjectBreath @BrendonStilesMD Ditto! Thanks @BrendonStilesMD! #LCSM |
| Sue McCullough @SueMcCu30398663 #LCSM Money collected in smoker's tax, spent on research and treatment or get the manufacturers to pay. |
| Brendon Stiles @BrendonStilesMD Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2ZpZT |
| LungCancer.net @LungCancer_HU RT @JFreemanDaily: T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvantaged community members, providers, researchers, payers, regulatory agencies, pharmacy benefit managers, pharma, biotech, advocates, nonprofits ... #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2ZpZT |
| Sue McCullough @SueMcCu30398663 #LCSM Oops should have put T5 |
| Brendon Stiles @BrendonStilesMD Please share your closing thoughts! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2ZpZT |
| Jill Feldman @jillfeldman4 T5 JUSTICE #LCSM #healthequity https://t.co/MBj4opWCTD |
| Linnea Olson @1111linno T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privilege. #lcsm |
| Dr. Amy C. Moore @acmoorephd @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network of Centers of Excellence #lcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh @BrendonStilesMD Ty this was enlightening and informative #lcsm |
| #LCSM Chat @lcsmchat RT @1111linno: T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privilege. #lcsm |
| #LCSM Chat @lcsmchat RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network of Centers of Excellence #lcsm |
| Linnea Olson @1111linno T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm |
| Sara Whitlock @sjwhitlock I think about this ALL the time. #LCSM |
| Brendon Stiles @BrendonStilesMD I would have loved to have spent time with all of you in Singapore! #lcsm #wclc20 Virtual conferences are more accessible and allow broader particpation, but I miss the face to face. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Walk the talk. #lcsm |
| #LCSM Chat @lcsmchat Thank you @BrendonStilesMD for moderating tonight. We appreciate you! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9 |
| #LCSM Chat @lcsmchat RT @1111linno: T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @bjork5: Big issue. I don’t have the answer, but every lung cancer patient deserves access to genomic testing and latests treatments, academic or community setting. @OneOncology @FoundationATCG #lcsm #PrecisionMedicine |
| Brendon Stiles @BrendonStilesMD Hoping |